Cargando…

An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease

It is generally believed that treatments are available to manage chorea in Huntington’s disease (HD). However, lack of evidence prevents the establishment of treatment guidelines. The HD chorea research literature fails to address the indications for drug treatment, drug selection, drug dosing and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgunder, Jean-Marc, Guttman, Mark, Perlman, Susan, Goodman, Nathan, van Kammen, Daniel P., Goodman, LaVonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166256/
https://www.ncbi.nlm.nih.gov/pubmed/21975581
http://dx.doi.org/10.1371/currents.RRN1260
_version_ 1782211136318341120
author Burgunder, Jean-Marc
Guttman, Mark
Perlman, Susan
Goodman, Nathan
van Kammen, Daniel P.
Goodman, LaVonne
author_facet Burgunder, Jean-Marc
Guttman, Mark
Perlman, Susan
Goodman, Nathan
van Kammen, Daniel P.
Goodman, LaVonne
author_sort Burgunder, Jean-Marc
collection PubMed
description It is generally believed that treatments are available to manage chorea in Huntington’s disease (HD). However, lack of evidence prevents the establishment of treatment guidelines. The HD chorea research literature fails to address the indications for drug treatment, drug selection, drug dosing and side effect profiles, management of inadequate response to a single drug, and preferred drug when behavioral symptoms comorbid to chorea are present. Because there is lack of an evidence base to inform clinical decision-making, we surveyed an international group of experts to address these points. Survey results showed that patient stigma, physical injury, gait instability, work interference, and disturbed sleep were indications for a drug treatment trial. However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia. All experts chose an APD when comorbid psychotic or aggressive behaviors were present, or when active depression prevented the use of TBZ. However, there was agreement from all geographic regions that both APDs and TBZ were acceptable as monotherapy in other situations. Perceived efficacy and side effect profiles were similar for APDs and TBZ, except for depression as a significant side effect of TBZ. Experts used a combination of an APD and TBZ when treatment required both drugs for control of chorea and a concurrent comorbid symptom, or when severe chorea was inadequately controlled by either drug alone. The benzodiazepines (BZDs) were judged ineffective as monotherapy but useful as adjunctive therapy, particularly when chorea was exacerbated by anxiety. There was broad disagreement about the use of amantadine for chorea. Experts who had used amantadine described its benefit as small and transient. In addition to survey results, this report reviews available chorea studies, and lastly presents an algorithm for the treatment of chorea in HD which is based on expert preferences obtained through this international survey.
format Online
Article
Text
id pubmed-3166256
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31662562011-10-04 An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease Burgunder, Jean-Marc Guttman, Mark Perlman, Susan Goodman, Nathan van Kammen, Daniel P. Goodman, LaVonne PLoS Curr Huntington Disease It is generally believed that treatments are available to manage chorea in Huntington’s disease (HD). However, lack of evidence prevents the establishment of treatment guidelines. The HD chorea research literature fails to address the indications for drug treatment, drug selection, drug dosing and side effect profiles, management of inadequate response to a single drug, and preferred drug when behavioral symptoms comorbid to chorea are present. Because there is lack of an evidence base to inform clinical decision-making, we surveyed an international group of experts to address these points. Survey results showed that patient stigma, physical injury, gait instability, work interference, and disturbed sleep were indications for a drug treatment trial. However, the experts did not agree on first choice of chorea drug, with the majority of experts in Europe favoring an antipsychotic drug (APD), and a near equal split in first choice between an APD and tetrabenazine (TBZ) among experts from North America and Australia. All experts chose an APD when comorbid psychotic or aggressive behaviors were present, or when active depression prevented the use of TBZ. However, there was agreement from all geographic regions that both APDs and TBZ were acceptable as monotherapy in other situations. Perceived efficacy and side effect profiles were similar for APDs and TBZ, except for depression as a significant side effect of TBZ. Experts used a combination of an APD and TBZ when treatment required both drugs for control of chorea and a concurrent comorbid symptom, or when severe chorea was inadequately controlled by either drug alone. The benzodiazepines (BZDs) were judged ineffective as monotherapy but useful as adjunctive therapy, particularly when chorea was exacerbated by anxiety. There was broad disagreement about the use of amantadine for chorea. Experts who had used amantadine described its benefit as small and transient. In addition to survey results, this report reviews available chorea studies, and lastly presents an algorithm for the treatment of chorea in HD which is based on expert preferences obtained through this international survey. Public Library of Science 2011-10-11 /pmc/articles/PMC3166256/ /pubmed/21975581 http://dx.doi.org/10.1371/currents.RRN1260 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Huntington Disease
Burgunder, Jean-Marc
Guttman, Mark
Perlman, Susan
Goodman, Nathan
van Kammen, Daniel P.
Goodman, LaVonne
An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
title An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
title_full An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
title_fullStr An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
title_full_unstemmed An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
title_short An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington’s Disease
title_sort international survey-based algorithm for the pharmacologic treatment of chorea in huntington’s disease
topic Huntington Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166256/
https://www.ncbi.nlm.nih.gov/pubmed/21975581
http://dx.doi.org/10.1371/currents.RRN1260
work_keys_str_mv AT burgunderjeanmarc aninternationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT guttmanmark aninternationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT perlmansusan aninternationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT goodmannathan aninternationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT vankammendanielp aninternationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT goodmanlavonne aninternationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT burgunderjeanmarc internationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT guttmanmark internationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT perlmansusan internationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT goodmannathan internationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT vankammendanielp internationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease
AT goodmanlavonne internationalsurveybasedalgorithmforthepharmacologictreatmentofchoreainhuntingtonsdisease